Plants traditionally used in age-related brain disorders (dementia): An ethanopharmacological survey

Pharmaceutical Biology

Volumn 51, Issue 4, 2013, Pages 492-523

  Natarajan, Suganthy ^a   Shunmugiah, Karutha Pandian ^a   Kasi, Pandima Devi ^a  

^a ALAGAPPA UNIVERSITY   (India)

Author keywords

Secretase; Acetylcholinesterase; Antioxidant; Butyrylcholinesterase; Phytoinhibitors

Indexed keywords

ALKALOID; ANGELICA ARCHANGELICA EXTRACT; ANGELICA EXTRACT; ANTIINFLAMMATORY AGENT; BETA SECRETASE INHIBITOR; BIOTA OREINTALIS EXTRACT; CARAGANA CHAMLAGUE EXTRACT; CENTELLA ASIATICA EXTRACT; CHOLINESTERASE INHIBITOR; CODONOPSIS PILOSULA EXTRACT; CORYNOLIN; DEHYDROEVODIAMINE; FLAVONOID; GALANTAMINE; GAMMA SECRETASE INHIBITOR; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HERBACEOUS AGENT; HUPERZINE A; MELISSA OFFICINALIS EXTRACT; MONOAMINE OXIDASE INHIBITOR; PHYSOSTIGMINE; PLACEBO; PLANT EXTRACT; PLANT GLYCOSIDE; PROTOPINE; RAMINYL; RIVASTIGMINE; SALVIA LAVANDULAEFOLIA EXTRACT; SYNAPTON; UNCLASSIFIED DRUG; UNINDEXED DRUG; WITHANIA SOMNIFERA EXTRACT;

ALZHEIMER DISEASE; AMNESIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY DISORDER; ATAXIA; BREATHING DISORDER; BUXUS; CARAGANA; CARAGANA CHAMLAGUE; CHEST TIGHTNESS; COGNITIVE DEFECT; CROCUS SATIVUS; DEMENTIA; DEPRESSION; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DOPAMINE BLOOD LEVEL; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; FATTY ACID SYNTHESIS; FUMARIA; GARLIC; GASTROINTESTINAL SYMPTOM; HUMAN; HUNTINGTON CHOREA; HYPERACTIVITY; HYSTERIA; INSOMNIA; LIVER TOXICITY; MAGNOLIA OFFICINALIS; MAGNOLIACEAE; MEDICINAL PLANT; MELANCHOLIA; MEMORY DISORDER; MIGRAINE; MULTIINFARCT DEMENTIA; MYASTHENIA GRAVIS; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROSIS; NONHUMAN; PARKINSON DISEASE; PLANT LEAF; PLANT ROOT; PRURITUS; REVIEW; SALVIA MILTIORRHIZA; SENILE DEMENTIA; SHORT TERM MEMORY; SIDE EFFECT; SKIN SWELLING; THORAX PAIN; TRADITIONAL MEDICINE; URTICARIA; VOMITING; WITHANIA SOMNIFERA;

AGE FACTORS; AGING; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CHOLINESTERASE INHIBITORS; COGNITION; DEMENTIA; ETHNOPHARMACOLOGY; HUMANS; MEMORY; NOOTROPIC AGENTS; PHYTOTHERAPY; PLANT PREPARATIONS; PLANTS, MEDICINAL; RISK FACTORS;

EID: 84875174028     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2012.738423     Document Type: Review

References (266)

1. Ahmad W, Ahmad B, Ahmad M, Iqbal Z, Nisar M, Ahmad M. (2003). In vitro inhibition of acetylcholinesterase, butyrylcholinesterase and lipoxygenase by crude extract of Myricaria elegans Royle. J Biol Sci, 3, 1046-1049.
2. Ahn EK, Jeon HJ, Lim EJ, Jung HJ, Park EH. (2007). Anti-infammatory and anti-angiogenic activities of Gastrodia elata Blume. J Ethnopharmacol, 110, 476-482.
3. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Grifn WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. (2000). Infammation and Alzheimer's disease. Neurobiol Aging, 21, 383-421.
4. Alcaraz MJ, Ferrándiz ML. (1987). Modifcation of arachidonic metabolism by favonoids. J Ethnopharmacol, 21, 209-229.
5. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C. (2001). Celastrol, a potent antioxidant and anti-infammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry, 25, 1341-1357.
6. Andrade MT, Lima JA, Pinto AC, Rezende CM, Carvalho MP, Epifanio RA. (2005). Indole alkaloids from Tabernaemontana australis (Muell. Arg) Miers that inhibit acetylcholinesterase enzyme. Bioorg Med Chem, 13, 4092-4095.
7. Aruoma OI, Spencer JP, Rossi R, Aeschbach R, Khan A, Mahmood N, Munoz A, Murcia A, Butler J, Halliwell B. (1996). An evaluation of the antioxidant and antiviral action of extracts of rosemary and Provençal herbs. Food Chem Toxicol, 34, 449-456.
8. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI. (1998). Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem, 273, 12817-12826.
9. Ayoola GA, Lawore FM, Adelowotan T, Aibinu IE, Adenipekun E, Coker HAB, Odugbemi TO. (2008). Chemical analysis and antimicrobial activity of the essential oil of Syzigium aromaticum (clove). Afr J Microbiol Res, 2, 162-166.
10. Barquet PG, Hosford D, Koltai M. (1994). Ginkgolide B (BN 52021): A natural PAF receptor antagonist. Neuropsychopharmacology, 10, 693S.
11. Bastianetto S, Ramassamy C, Doré S, Christen Y, Poirier J, Quirion R. (2000a). The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci, 12, 1882-1890.
12. Bastianetto S, Zheng WH, Quirion R. (2000b). The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: Involvement of its favonoid constituents and protein kinase C. J Neurochem, 74, 2268-2277.
13. Begum VH, Sadique J. (1988). Long term efect of herbal drug Withania somnifera on adjuvant induced arthritis in rats. Indian J Exp Biol, 26, 877-882.
14. Bhattacharya A, Ghosal S, Bhattacharya SK. (2001). Anti-oxidant efect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J Ethnopharmacol, 74, 1-6.
15. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. (2000). Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res, 14, 174-179.
16. Bhattacharya SK, Kumar A, Ghosal S. (1995). Efects of glycowithanolides from Withania somnifera on an animal model of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. Phytother Res, 9, 110-113.
17. Bingol F, Sener B. (1995). A review of terrestrial plants and marine organisms having anti-infammatory activity. Int J Pharm, 33, 81-97.
18. Birkmayer JGD. (1996). Coenzyme nicotinamide adenine dinucleotide. New therapeutic approach to improving dementia of the Alzheimers type. Ann Clin Lab Sci, 26, 1-9.
19. Bisset NG. (1994). Herbal drugs and phytopharmaceuticals. Stuttgart: Med. PharmGmbH, Scientifc Publishers.
20. Borek C. (2001). Antioxidant health efects of aged garlic extract. J Nutr, 131, 1010S-1015S.
21. Bouchet N, Barrier L, Fauconneau B. (1998). Radical scavenging activity and antioxidant properties of tannins form Guiera senegalensis (Combretaceae). Phytother Res, 12, 159-162.
22. Brandt J, Butters N. (1986). The neuropsychology of Huntington's disease. Trends Neurosc, 9, 118-120.
23. Brandt J, Folstein SE, Folstein MF. (1988). Diferential cognitive impairment in Alzheimer's disease and Huntington's disease. Ann Neurol, 23, 555-561.
24. Breitner JC. (1996). The role of anti-infammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med, 47, 401-411.
25. Brown MM. (1993). Vascular dementia. Alzheimer's Rev, 3, 57-62.
26. Brown RC, Lockwood AH, Sonawane BR. (2005). Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect, 113, 1250-1256.
27. Brufani M, Filocamo L. (2000). Rational design of cholinesterase inhibitors. In: Giacobini E, ed. Cholinesterase and Cholinesterase Inhibitors. London: Martin Dunitz, 27-46.
28. Bustamam A, Ibrahim S, Al-Zubairi A, Met M, Syam MM. (2008). Zerumbone: A natural compound with anti-cholinesterase activity. Am J Pharmacol Toxicol, 3, 209-211.
29. Chao J, Lu TC, Liao JW, Huang TH, Lee MS, Cheng HY, Ho LK, Kuo CL, Peng WH. (2009). Analgesic and anti-infammatory activities of ethanol root extract of Mahonia oiwakensis in mice. J Ethnopharmacol, 125, 297-303.
30. Chauhan N, Wang KC, Wegiel J, Malik MN. (2004). Walnut extract inhibits the fbrillization of amyloid beta-protein, and also defbrillizes its preformed fbrils. Curr Alzheimer Res, 1, 183-188.
31. Chauhan V, Chauhan A. (2006). Oxidative stress in Alzheimer's disease. Pathophysiology, 13, 195-208.
32. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, Bush AI. (1999). Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem, 274, 23223-23228.
33. Cho JK, Ryu YB, Curtis-Long MJ, Kim JY, Kim D, Lee S, Lee WS, Park KH. (2011). Inhibition and structural reliability of prenylated favones from the stem bark of Morus lhou on β-secretase (BACE-1). Bioorg Med Chem Lett, 21, 2945-2948.
34. Choi MS, Lee SH, Cho HS, Kim Y, Yun YP, Jung HY, Jung JK, Lee BC, Pyo HB, Hong JT. (2007). Inhibitory efect of obovatol on nitric oxide production and activation of NF-kappaB/MAP kinases in lipopolysaccharide-treated RAW 264.7cells. Eur J Pharmacol, 556, 181-189.
35. Choi SH, Hur JM, Yang EJ, Jun M, Park HJ, Lee KB, Moon E, Song KS. (2008). Beta-secretase (BACE1) inhibitors from Perilla frutescens var. acuta. Arch Pharm Res, 31, 183-187.
36. Choi SJ, Kim MJ, Heo HJ, Hong B, Cho HY, Kim YJ, Kim HK, Lim ST, Jun WJ, Kim EK, Shin DH. (2007). Ameliorating efect of Gardenia jasminoides extract on amyloid beta peptide-induced neuronal cell defcit. Mol Cells, 24, 113-118.
37. Choi YH, Yon GH, Hong KS, Yoo DS, Choi CW, Park WK, Kong JY, Kim YS, Ryu SY. (2008). In vitro BACE-1 inhibitory phenolic components from the seeds of Psoralea corylifolia. Planta Med, 74, 1405-1408.
38. Choi YH, Yoo MY, Choi CW, Cha MR, Yon GH, Kwon DY, Kim YS, Park WK, Ryu SY. (2009). A new specifc BACE-1 inhibitor from the stembark extract of Vitis vinifera. Planta Med, 75, 537-540.
39. Choi YW, Takamatsu S, Khan SI, Srinivas PV, Ferreira D, Zhao J, Khan IA. (2006). Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: Structure-antioxidant activity relationships of dibenzocyclooctadiene lignans. J Nat Prod, 69, 356-359.
40. Chopin P, Briley M. (1992). Efects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology (Berl), 106, 26-30.
41. Chu GX, Chen X. (1990). Anti-lipid peroxidation and protection of ginsenosides against cerebral ischemia-reperfusion injuries in rats. Zhongguo Yao Li Xue Bao, 11, 119-123.
42. Chung YK, Heo HJ, Kim EK, Kim HK, Huh TL, Lim Y, Kim SK, Shin DH. (2001). Inhibitory efect of ursolic acid purifed from Origanum majorana L on the acetylcholinesterase. Mol Cells, 11, 137-143.
43. Coelho Filho JMJMC, Birks J. (2008). Physostigmine for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews, Issue 4, The Cochrane Collaboration. UK: JohnWiley & Sons.
44. Conti-Fine BM, Milani M, Kaminski HJ. (2006). Myasthenia gravis: Past, present, and future. J Clin Invest, 116, 2843-2854.
45. Coppede F, Mancuso M, Siciliano G, Migliore L, Murri L. (2006). Genes and the environment in neurodegeneration. Biosci Rep, 26, 341-367.
46. Craig S, Barik A, Mishra B, Shen L, Mohan H, Kadam RM, Dutta S, Zhang HY, Priyadarsini KI. (2005). Evaluation of new copper-cumumin complex as superoxide dismutase mimic and its free radical reactions. Free Radical Biol Med, 39, 811-822.
47. Crelin JK, Philpott J. (1990). Herbal Medicine Past and Present. Vol 2. A Reference Guide to Medicinal Plants. Durham: Duke University.
48. Cuvelier M, Richard H, Berset C. (1996). Antioxidative activity and phenolic composition of pilot plant and commercial extracts of sage and rosemary. JAOCS, 73, 645-652.
49. Dai Q, Borenstein AR, Wu Y, Jackson JC, Larson EB. (2006). Fruit and vegetable juices and Alzheimer's disease: The Kame Project. Am J Med, 119, 751-759.
50. Das A, Shanker G, Nath C, Pal R, Singh S, Singh H. (2002). A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: Anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav, 73, 893-900.
51. Datla KP, Christidou MA, Widmer WW, Rooparai HK, Dexter DT. (2002). Citrus favonoid tangeretin accumulates in the brain and pre-treatment protects against dopaminergic neuronal loss in a rat model of Parkinson's disease. Brit J Pharmacol, 135.
52. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. (1999). Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA, 281, 1401-1406.
53. de la Puerta R, Forder RA, Hoult JRS. (1999). Inhibition of leukocyte eicosanoid generation and radical scavenging activity by gnaphalin, a lipophilic favonol isolated from Helichrvsum bicardii. Planta Med, 65, 507-511.
54. Deans SG, Noble RC, Penzes L, Beregi E. (1993). Natural antioxidants from aromatic and medicinal plants. In: Feher J, Blazovics A, Matkovics B, Akademiai kiado MM, eds. Role of Free Radicals in Biological Systems. Budapest, 159-165.
55. Dewachter I, Van Leuven F. (2002). Secretases as targets for the treatment of Alzheimer's disease: The prospects. Lancet Neurol, 1, 409-416.
56. Dhuley JN. (1997). Efect of some Indian herbs on macrophage functions in ochratoxin A treated mice. J Ethnopharmacol, 58, 15-20.
57. Diermen DV, Marstona A, Bravo J, Reist M, Carrupt PA, Hostettmann K. (2009). Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethanopharmacol, 122, 397-401.
58. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Torsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD, Audia JE. (2001). Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem, 76, 173-181.
59. Du GH, Qiu Y, Zhang JT. (2000). Salvianolic acid B protects the memory functions against transient cerebral ischemia in mice. J Asian Nat Prod Res, 2, 145-152.
60. Durairajan SS, Yuan Q, Xie L, Chan WS, Kum WF, Koo I, Liu C, Song Y, Huang JD, Klein WL, Li M. (2008). Salvianolic acid B inhibits Abeta fbril formation and disaggregates preformed fbrils and protects against Abeta-induced cytotoxicty. Neurochem Int, 52, 741-750.
61. Emerit J, Edeas M, Bricaire F. (2004). Neurodegenerative diseases and oxidative stress. Biomed Pharmacother, 58, 39-46.
62. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. (1993). Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease. Prog Brain Res, 98, 431-438.
63. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. (2002). Efcacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet, 359, 1283-1290.
64. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. (1989). Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA, 262, 2551-2556.
65. Farlow M. (2002). A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr, 14 Suppl 1, 93-126.
66. Fein G, Di Sclafani V, Tanabe J, Cardenas V, Weiner MW, Jagust WJ, Reed BR, Norman D, Schuf N, Kusdra L, Greenfeld T, Chui H. (2000). Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology, 55, 1626-1635.
67. Folstein SE. (1989). Huntington's disease: A disorder of families. Baltimore: Johns Hopkins University Press.
68. Forman MS, Trojanowski JQ, Lee VM. (2004). Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nat Med, 10, 1055-1063.
69. Foye WO, Lemke TL, Williams DA. (1995). Pharmacodyanmic agents. In: Principles of Medicinal Chemistry (5th Ed.). New York: Williams and Wilkins, 278-279.
70. Genovese S, Foreman JE, Borland MG, Epifano F, Gonzalez FJ, Curini M, Peters JM. (2010). A natural propenoic acid derivative activates peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Life Sci, 86, 493-498.
71. Gilani AH, Ghayur MN, Ahmed SP, Saify Z, Choudhary MI, Khalid A. (2002). The presence of cholinergic and acetylcholinesterase inhibitory constituents in betel nut. Abstract Book of 7th Eurasia Conference on Chemical Sciences, H.E.J. Research Institute of Chemistry, March 8-12, Karachi, Pakistan.
72. Grifn B. (1998). Efect of aged garlic extract on the cytotoxicity of Alzheimer beta amyloid peptide in neuronal PC12 cells. Nutr Neurosci, 3, 132-142.
73. Grundman M, Grundman M, Delaney P. (2002). Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc, 61, 191-202.
74. Hagnell O, Franck A, Gräsbeck A, Ohman R, Ojesjö L, Otterbeck L, Rorsman B. (1992). Vascular dementia in the Lundby study. 1. A prospective, epidemiological study of incidence and risk from 1957 to 1972. Neuropsychobiology, 26, 43-49.
75. Haraguchi H, Tanaka Y, Kabbash A, Fujioka T, Ishizu T, Yagi A. (2004). Monoamine oxidase inhibitors from Gentiana lutea. Phytochemistry, 65, 2255-2260.
76. Harbone JB, Baxter H. (1993). Phytochemical Dictionary. London: Taylor and Francis.
77. Heidebrink JL. (2002). Is dementia with Lewy bodies the second most common cause of dementia? J Geriatr Psychiatry Neurol, 15, 182-187.
78. Ho L, Purohit D, Haroutunian V, Luterman JD, Willis F, Naslund J, Buxbaum JD, Mohs RC, Aisen PS, Pasinetti GM. (2001). Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol, 58, 487-492.
79. Holden M, Kelly C. (2002). Use of cholinesterase inhibitors in dementia. APT, 8, 89-96.
80. Hong M, Lee VM. (1997). Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem, 272, 19547-19553.
81. Hoozemans JJ, Veerhuis R, Rozemuller AJ, Eikelenboom P. (2003). Non-steroidal anti-infammatory drugs and cyclooxygenase in Alzheimer's disease. Curr Drug Targets, 4, 461-468.
82. Hou WC, Lin RD, Chen CT, Lee MH. (2005). Monoamine oxidase B (MAO-B) inhibition by active principles from Uncaria rhynchophylla. J Ethnopharmacol, 100, 216-220.
83. Huang KC. (1993). The pharmacology of Chinese herbs. CRC press, BocaRaton (FL), 81-84.
84. Hughes AJ, Daniel SE, Kilford L, Lees AJ. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr, 55, 181-184.
85. Hwang EM, Ryu YB, Kim HY, Kim DG, Hong SG, Lee JH, Curtis-Long MJ, Jeong SH, Park JY, Park KH. (2008). BACE1 inhibitory efects of lavandulyl favanones from Sophora favescens. Bioorg Med Chem, 16, 6669-6674.
86. Ingkaninan K, de Best CM, van der Heijden R, Hofte AJ, Karabatak B, Irth H, Tjaden UR, van der Greef J, Verpoorte R. (2000). Highperformance liquid chromatography with on-line coupled UV, mass spectrometric and biochemical detection for identifcation of acetylcholinesterase inhibitors from natural products. J Chromatogr A, 872, 61-73.
87. Ingkaninan K, Temkitthawon P, Chuenchom K, Yuyaem T, Tongnoi W. (2003). Screening for acetylcholinesterase inhibitory activity in plants used in Tai traditional rejuvenating and neurotonic remedies. J Ethnopharmacol, 89, 261-264.
88. Itoh T, Zang YF, Murai S, Saito H. (1989). Efects of Panax ginseng root on the vertical and horizontal motor activities and on brain monoamine-related substances in mice. Planta Med, 55, 429-433.
89. Jain S, Shukla SD, Sharma K, Bhatnagar M. (2001). Neuroprotective efects of Withania somnifera Dunn. in hippocampal sub-regions of female albino rat. Phytother Res, 15, 544-548.
90. Jankovic J. (2008). Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatr, 79, 368-376.
91. Jenkinson ML, Bliss MR, Brain AT, Scott DL. (1989). Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol, 28, 86-88.
92. Jeon SY, Bae K, Seong YH, Song KS. (2003). Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett, 13, 3905-3908.
93. Jeon SY, Kwon SH, Seong YH, Bae K, Hur JM, Lee YY, Suh DY, Song KS. (2007). Beta-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma. Phytomedicine, 14, 403-408.
94. Jia H, Jiang Y, Ruan Y, Zhang Y, Ma X, Zhang J, Beyreuther K, Tu P, Zhang D. (2004). Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells. Neurosci Lett, 367, 123-128.
95. Jiang F, DeSilva S, Turnbull J. (2000). Benefcial efect of ginseng root in SOD-1 (G93A) transgenic mice. J Neurol Sci, 180, 52-54.
96. Jamie T. (2010). In a large clinical trial, γ secretase inibitro tarenfurbil is found inefective for mild Alzheimer disease. Neurol Today 10, 16-17.
97. Joseph JA, Shukitt-Hale B, Brewer GJ, Weikel KA, Kalt W, Fisher DR. (2010). Diferential protection among fractionated blueberry polyphenolic families against DA-, Abeta(42)-and LPS-induced decrements in Ca(2+) bufering in primary hippocampal cells. J Agric Food Chem, 58, 8196-8204.
98. Jung AYH, Byung-Sun MIN, Yokozawa T, Lee JH, Kim YS, Choi JS. (2009). Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids. Biol Pharm Bull, 32, 1433-1438.
99. Jung HA, Lee EJ, Kim JS, Kang SS, Lee JH, Min BS, Choi JS. (2009). Cholinesterase and BACE1 inhibitory diterpenoids from Aralia cordata. Arch Pharm Res, 32, 1399-1408.
100. Jung HW, Yoon CH, Park KM, Han HS, Park YK. (2009). Hexane fraction of Zingiberis Rhizoma Crudus extract inhibits the production of nitric oxide and proinfammatory cytokines in LPS-stimulated BV2 microglial cells via the NF-kappaB pathway. Food Chem Toxicol, 47, 1190-1197.
101. Jung M, Park M. (2007). Acetylcholinesterase inhibition by favonoids from Agrimonia pilosa. Molecules, 12, 2130-2139.
102. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, Luchsinger JA, Ogunniyi A, Perry EK, Potocnik F, Prince M, Stewart R, Wimo A, Zhang ZX, Antuono P; World Federation of Neurology Dementia Research Group. (2008). Alzheimer's disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol, 7, 812-826.
103. Kang HS, Chung HY, Jung JH, Kang SS, Choi JS. (1997). Antioxidant efect of Salvia miltiorrhiza. Arch Pharm Res, 20, 496-500.
104. Kapoor LD. (1990). Hand book of Ayurvedic Medicinal Plants. Boca Raton: CRC Press.
105. Kenner D, Requena Y. (1996). Botanical medicine: A European professional prespective. Paradigm, Brookline.
106. Kidd PM. (2000). Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev, 5, 502-529.
107. Kim DK, Lee KT, Baek NI, Kim SH, Park HW, Lim JP, Shin TY, Eom DO, Yang JH, Eun JS. (2004). Acetylcholinesterase inhibitors from the aerial parts of Corydalis speciosa. Arch Pharm Res, 27, 1127-1131.
108. Kim DK. (2002). Inhibitory efect of corynoline isolated from the aerial parts of Corydalis incisa on the acetylcholinesterase. Arch Pharm Res, 25, 817-819.
109. Kim HM, Lee EH, Na HJ, Lee SB, Shin TY, Lyu YS, Kim NS, Nomura S. (1998). Efect of polygala tenuifolia root extract on the tumour necrosis factor alpha secretion from mouse astrocytes. J Ethnophamacol, 61, 201-208.
110. Kim HS, Lim JY, Sul D, Hwang BY, Won TJ, Hwang KW, Park SY. (2009). Neuroprotective efects of the new diterpene, CBNU06 against beta-amyloid-induced toxicity through the inhibition of NF-kappaB signaling pathway in PC12 cells. Eur J Pharmacol, 622, 25-31.
111. Kim JY, Jung KJ, Choi JS, Chung HY. (2006). Modulation of the age-related nuclear factor-kappaB (NF-kappaB) pathway by hesperetin. Aging Cell, 5, 401-411.
112. Kim S, Ahn K, Oh TH, Nah SY, Rhim H. (2002). Inhibitory efect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem Biophys Res Commun, 296, 247-254.
113. Kim SJ, Jeong HJ, Lee KM, Myung NY, An NH, Yang WM, Park SK, Lee HJ, Hong SH, Kim HM, Um JY. (2007). Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem, 18, 587-596.
114. Kim SR, Sung SH, Lim DY, Kim H, Choi H, Park HK, Jew SS, Kim YC, Lee MK. (2000). Asiatic acid derivatives protect cultured neurons from glutamate-induced excitotoxicity. Res Commun Mol Pathol Pharmacol, 108, 75-86.
115. Kishnani PS, Sullivan JA, Walter BK, Spiridigliozzi GA, Doraiswamy PM, Krishnan KR. (1999). Cholinergic therapy for Down's syndrome. Lancet, 353, 1064-1065.
116. Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B. (2003). New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol, 77, 10288-10294.
117. Kristofkova Z, Benesova O, Tejkalova H. (1992). Changes of high afnity choline uptake in the hippocampus of old rats after longterm administration of two nootropic drugs (tacrine and Ginkgo biloba). Dementia, 3, 304-307.
118. Kuang P, Li Z, Zhang F, Tao Y, Liu J, Wu W. (1995). Protective efect of Radix Salviae miltiorrhizae composite on cerebral ischemia. JTCM, 16, 224-227.
119. Kuang P, Tao Y, Tian Y. (1996). Efect of radix Salviae miltiorrhizae on nitric oxide in cerebral ischemic-reperfusion injury. J Tradit Chin Med, 16, 224-227.
120. Kuang P, Wu W, Liu J, Zhang F, Pu C. (1991). The efect of radix Salviae miltiorrhizae (RSM) on substance P in cerebral ischemia-animal experiment. J Tradit Chin Med, 11, 123-127.
121. Kuang P, Wu W, Zhang F, Liu J, Pu C. (1989). The efect of Radix Salviae miltiorrhizae on vasoactive intenstinal peptide in cerebral ischaemia: an animal experiment. JTCM, 9, 203-206.
122. Kuang P, Wu W, Zhu K. (1993). Evidence for amelioration of cellular damage in ischemic rat brain by radix Salviae miltiorrhizae treatment- immunocytochemistry and histopathology studies. J Tradit Chin Med, 13, 38-41.
123. Kuang P, Xiang J. (1994). Efect of radix Salviae miltiorrhizae on EAA and IAA during cerebral ischemia in gerbils: a microdialysis study. J Tradit Chin Med, 14, 45-50.
124. Kumar S, Harris RJ, Seal CJ, Okello EJ. (2012). An aqueous extract of Withania somnifera root inhibits amyloid β fbril formation in vitro. Phytother Res, 26, 113-117.
125. Kwak HM, Jeon SY, Sohng BH, Kim JG, Lee JM, Lee KB, Jeong HH, Hur JM, Kang YH, Song KS. (2005). beta-Secretase (BACE1) inhibitors from pomegranate (Punica granatum) husk. Arch Pharm Res, 28, 1328-1332.
126. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. (2001). The anti-infammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol, 8, 759-766.
127. Le Bars PL, Kieser M, Itil KZ. (2000). A 26-week analysis of a doubleblind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord, 11, 230-237.
128. Lee MK, Kim SR, Sung SH, Lim D, Kim H, Choi H, Park HK, Je S, Ki YC. (2000). Asiatic acid derivatives protect cultured cortical neurons from glutamate-induced excitotoxicity. Res Commun Mol Pathol Pharmacol, 108, 75-86.
129. Lee HJ, Seong YH, Bae KH, Kwon SH, Kwak HM, Nho SK, Kim KA, Hur JM, Lee KB, Kang YH, Song KS. (2005). beta-Secretase (BACE1) inhibitors from Sanguisorbae Radix. Arch Pharm Res, 28, 799-803.
130. Lee MH, Lin RD, Shen LY, Yang LL, Yen KY, Hou WC. (2001a). Monoamine oxidase B and free radical scavenging activities of natural favonoids in Melastoma candidum D. Don. J Agric Food Chem, 49, 5551-5555.
131. Lee TF, Shiao YJ, Chen CF, Wang LC. (2001b). Efect of ginseng saponins on beta-amyloid-suppressed acetylcholine release from rat hippocampal slices. Planta Med, 67, 634-637.
132. Lee YK, Sung SH, Kim YC. (2003). New acetylcholinesterase-inhibitory pregnane glycosides of Cynanchum atratum roots. Helv Chim Acta, 86, 474-483.
133. Lee YK, Yuk DY, Lee JW, Lee SY, Ha TY, Oh KW, Yun YP, Hong JT. (2009). (-)-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory defciency. Brain Res, 1250, 164-174.
134. Lim JY, Won TJ, Hwang BY, Kim HR, Hwang KW, Sul D, Park SY. (2010). The new diterpene isodojaponin D inhibited LPS-induced microglial activation through NF-kappaB and MAPK signaling pathways. Eur J Pharmacol, 642, 10-18.
135. Limpeanchob N, Jaipan S, Rattanakaruna S, Phrompittayarat W, Ingkaninan K. (2008). Neuroprotective efect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J Ethnopharmacol, 120, 112-117.
136. Lin RD, Hou WC, Yen KY, Lee MH. (2003). Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines.
137. Löfer T, Lee SK, Nöldner M, Chatterjee SS, Hoyer S, Schliebs R. (2001). Efect of Ginkgo biloba extract (EGb761) on glucose metabolism-related markers in streptozotocin-damaged rat brain. J Neural Transm, 108, 1457-1474.
138. López S, Bastida J, Viladomat F, Codina C. (2002). Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts. Life Sci, 71, 2521-2529.
139. Lu DY, Tang CH, Chen YH, Wei IH. (2010). Berberine suppresses neuroinfammatory responses through AMP-activated protein kinase activation in BV-2 microglia. J Cell Biochem, 110, 697-705.
140. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko P. (2002). Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA, 99, 12197-12202.
141. Lv L, Yang QY, Zhao Y, Yao CS, Sun Y, Yang EJ, Song KS, Mook-Jung I, Fang WS. (2008). BACE1 (beta-secretase) inhibitory chromone glycosides from Aloe vera and Aloe nobilis. Planta Med, 74, 540-545.
142. Ma WG, Fukushi Y, Tahara S. (1999). Fungitoxic alkaloids from Hokkaido corydalis species. Fitoterapia, 70, 258-265.
143. Maggini M, Vanacore N, Raschetti R. (2006). Cholinesterase inhibitors: Drugs looking for a disease? PLoS Med, 3, e140.
144. Mandel S, Weinreb O, Amit T, Youdim MB. (2004). Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin- 3-gallate: Implications for neurodegenerative diseases. J Neurochem, 88, 1555-1569.
145. Marcocci L, Packer L, Droy-Lefaix MT, Sekaki A, Gardès-Albert M. (1994). Antioxidant action of Ginkgo biloba extract EGb 761. Meth Enzymol, 234, 462-475.
146. Marumoto S, Miyazawa M. (2010). beta-Secretase inhibitory efects of furanocoumarins from the root of Angelica dahurica. Phytother Res, 24, 510-513.
147. Masaki H, Atsumi T, Sakurai H. (1995). Peroxyl radical scavenging activities of hamamelitannin in chemical and biological systems. Free Radic Res, 22, 419-430.
148. Mattson MP. (2003). Gene-diet interactions in brain aging and neurodegenerative disorders. Ann Intern Med, 139, 441-444.
149. Mattson MP. (2004). Pathways towards and away from Alzheimer's disease. Nature, 430, 631-639.
150. Mayeux R. (2003). Epidemiology of neurodegeneration. Annu Rev Neurosci, 26, 81-104.
151. McGeer PL, Schulzer M, McGeer EG. (1996). Arthritis and anti-infammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology, 47, 425-432.
152. McVicar J. (1994). Jekka's Complete Herb Book. London: Kyle Cathie.
153. Melzer D, Ely M, Brayne C. (1997). Cognitive impairment in elderly people: Population based estimate of the future in England, Scotland, and Wales. BMJ, 315, 462.
154. Miranda S, Opazo C, Larrondo LF, Muñoz FJ, Ruiz F, Leighton F, Inestrosa NC. (2000). The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog Neurobiol, 62, 633-648.
155. Miyazawa M, Watanabe H, Kameoka H. (1997). Inhibition of acetylcholinesterase activity by monoterpenoids with a p methane skeleton. J Agric Food Chem, 45, 677-679.
156. Moriguchi T, Nishiyama N, Saito H, Katsuki H. (1996). Trophic efects of aged garlic extract (AGE) and its fraction on primary cultured hippocampal neurons from fetal rat brain. Phytother Res, 10, 468-472.
157. Moriguchi T, Saito H, Nishiyama N. (1997). Anti-ageing efect of aged garlic extract in the inbred brain atrophy mouse model. Clin Exp Pharmacol Physiol, 24, 235-242.
158. Moussaief A, Shohami E, Kashman Y, Fride E, Schmitz ML, Renner F, Fiebich BL, Munoz E, Ben-Neriah Y, Mechoulam R. (2007). Incensole acetate, a novel anti-infammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation. Mol Pharmacol, 72, 1657-1664.
159. Nalini K, Aroor AR, Karanth KS, Rao A. (1992). Efect of Centella asiatica fresh leaf aqueous extract on learning and memory and biogenic amine turnover in albino rats. Fitoterapia, 63, 232-238.
160. Newhouse PA, Kelton M. (2000). Nicotinic systems in central nervous systems disease: degenerative disorders and beyond. Pharm Acta Helv, 74, 91-101.
161. Numagami Y, Sato S, Ohnishi ST. (1996). Attenuation of rat ischemic brain damage by aged garlic extracts: a possible protecting mechanism as antioxidants. Neurochem Int, 29, 135-143.
162. Ock J, Han HS, Hong SH, Lee SY, Han YM, Kwon BM, Suk K. (2010). Obovatol attenuates microglia-mediated neuroinfammation by modulating redox regulation. Br J Pharmacol, 159, 1646-1662.
163. Oh MH, Houghton PJ, Whang WK, Cho JH. (2004). Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine, 11, 544-548.
164. Okello EJ, Savelev SU, Perry EK. (2004). In vitro anti-beta-secretase and dual anti-cholinesterase activities of Camellia sinensis L. (tea) relevant to treatment of dementia. Phytother Res, 18, 624-627.
165. Oken BS, Storzbach DM, Kaye JA. (1998). The efcacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol, 55, 1409-1415.
166. Olsen HT, Staford GI, van Staden J, Christensen SB, Jäger AK. (2008). Isolation of the MAO-inhibitor naringenin from Mentha aquatica L. J Ethnopharmacol, 117, 500-502.
167. Ono K, Hasegawa K, Naiki H, Yamada M. (2004a). Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fbrils in vitro. Biochim Biophys Acta, 1690, 193-202.
168. Ono K, Hasegawa K, Naiki H, Yamada M. (2004b). Curcumin has potent anti-amyloidogenic efects for Alzheimer's beta-amyloid fbrils in vitro. J Neurosci Res, 75, 742-750.
169. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. (2003). Potent anti-amyloidogenic and fbril-destabilizing efects of polyphenols in
170. Orhan E, Aslan S, Kartal M, Sener B, Baser KHC. (2007). Inhibitory efect of Turkish Rosmarinus ofcinalis L. on acetylcholinesterase and butyrylcholinesterase enzymes. Food Chem, 108, 663-668.
171. Orhan I, Sener B, Choudhary MI, Khalid A. (2004). Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. J Ethnopharmacol, 91, 57-60.
172. Orhan I, Terzioglu S, Sener B. (2003). Alpha-onocerin: An acetylcholinesterase inhibitor from Lycopodium clavatum. Planta Med, 69, 265-267.
173. Park CH, Kim SH, Choi W, Lee YJ, Kim JS, Kang SS, Suh YH. (1996). Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Planta Med, 62, 405-409.
174. Park CH, Lee YJ, Lee SH, Choi SH, Kim HS, Jeong SJ, Kim SS, Suh YH. (2000). Dehydroevodiamine. HCl prevents impairment of learning and memory and neuronal loss in rat models of cognitive disturbance. J Neurochem, 74, 244-253.
175. Park J, Cho JY. (2009). Antiinfammtory efects of ginsenosides from Panax ginseng and their structural analogs. Afr J Biotechnol, 8, 3682-3690.
176. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH. (1985). Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatr, 48, 413-421.
177. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, Honavar M, Dean A, Grifths M, McKeith IG. (1994). Neocortical cholinergic activities diferentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport, 5, 747-749.
178. Perry N, Court G, Bidet N, Court J, Perry E. (1996). European herbs with cholinergic activities: Potential in dementia therapy. Int J Geriatr Psychiatry, 11, 1063-1069.
179. Perry NS, Houghton PJ, Jenner P, Keith A, Perry EK. (2002). Salvia lavandulaefolia essential oil inhibits cholinesterase in vivo. Phytomedicine, 9, 48-51.
180. Perry NS, Bollen C, Perry EK, Ballard C. (2003). Salvia for dementia therapy: Review of pharmacological activity and pilot tolerability clinical trial. Pharmacol Biochem Behav, 75, 651-659.
181. Perry NS, Houghton PJ, Teobald A, Jenner P, Perry EK. (2000). In-vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol, 52, 895-902.
182. Petit A, Bihel F, Alvès da Costa C, Pourquié O, Checler F, Kraus JL. (2001). New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without afecting Notch cleavage. Nat Cell Biol, 3, 507-511.
183. Petkov VD, Kehayov R, Belcheva S, Konstantinova E, Petkov VV, Getova D, Markovska V. (1993). Memory efects of standardized extracts of Panax ginseng (G115), Ginkgo biloba (GK 501) and their combination Gincosan (PHL-00701). Planta Med, 59, 106-114.
184. Poirier J. (2002). Evidence that the clinical efects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl, 127, 6-19.
185. Pollanen MS, Dickson DW, Bergeron C. (1993). Pathology and biology of the Lewy body. J Neuropathol Exp Neurol, 52, 183-191.
186. Rahman AU, Choudhary MI. (2001). Bioactive natural products as a potential source of new pharmacophores a theory of memory. Pure Appl chem, 73, 555-560.
187. Rahman A-ur, Parveen S, Khalid A, Farooq A, Ayattollahi SAM, Choudhary MI. (1998). Acetylcholinesterase inhibiting triterpenoidal alkaloids from Buxus hyrcana. Heterocycle, 49, 481-488.
188. Rajakrishnan V, Viswanathan P, Rajasekharan KN, Menon VP. (1999). Neuroprotective role of curcumin from Curcuma longa on ethanol-induced brain damage. Phytother Res, 13, 571-574.
189. Ramesh BN, Indi SS, Rao KS. (2010). Anti-amyloidogenic property of leaf aqueous extract of Caesalpinia crista. Neurosci Lett, 475, 110-114.
190. Ren Y, Houghton PJ, Hider RC, Howes MJ. (2004). Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. Planta Med, 70, 201-204.
191. Rhee IK, van de Meent M, Ingkaninan K, Verpoorte R. (2001). Screening for acetylcholinesterase inhibitors from Amaryllidaceae using silica gel thin-layer chromatography in combination with bioactivity staining. J Chromatogr A, 915, 217-223.
192. Rice-Evans CA, Miller NJ, Paganga G. (1996). Structure-antioxidant activity relationships of favonoids and phenolic acids. Free Radic Biol Med, 20, 933-956.
193. Rigney U, Kimber S, Hindmarch I. (1999). The efects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytother Res, 13, 408-415.
194. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. (2003). Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol, 60, 1685-1691.
195. Roddick JG. (1989). The acetylcholinesterase inhibitory activity of steroidal glycoalkaloids and their aglycones. Phytochemistry, 28, 2631-2634.
196. Roman GC. (2003). Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc, 51, S296-S304.
197. Ross IA. (2001). Medicinal Plants of the World (Vol 2). Chemical Constituents, Traditional and Modern Medicinal Uses. New Jersey: Humana Press.
198. Rudakewich M, Ba F, Benishin CG. (2001). Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1). Planta Med, 67, 533-537.
199. Sakina MR, Dandiya PC. (1990). A psycho-neuropharmacological profle of Centella asiatica extract. Fitoterapia, 61, 291-296.
200. Savelev SU, Okello EJ, Perry EK. (2004). Butyryl-and acetyl- cholinesterase inhibitory activities in essential oils of Salvia species and their constituents. Phytother Res, 18, 315-324.
201. Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal S, Bigl V. (1997). Systemic administration of defned extracts from Withania somnifera (Indian Ginseng) and Shilajit diferentially afects cholinergic but not glutamatergic and GABAergic markers in rat brain. Neurochem Int, 30, 181-190.
202. Schwarz MJ, Houghton PJ, Rose S, Jenner P, Lees AD. (2003). Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism. Pharmacol Biochem Behav, 75, 627-633.
203. Selkoe DJ. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol Rev, 81, 741-766.
204. Shen L, Zhang J. (2003). Ginsenoside Rg1 increases ischemia-induced cell proliferation and survival in the dentate gyrus of adult gerbils. Neurosci Lett, 344, 1-4.
205. Siddiqui MF, Levey AI. (1999). Cholinergic therapies in Alzheimer's disease. Drug Future, 24, 417-444.
206. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC. (2007). Safety, tolerability, and efects on plasma and cerebrospinal fuid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol, 30, 317-325.
207. Singh A, Naidu PS, Kulkarni SK. (2003). Quercetin potentiates l-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition. Pharmacology, 68, 81-88.
208. Sisodia SS. (1999). Alzheimer's disease: Perspectives for the new millennium. J Clin Invest, 104, 1169-1170.
209. Sleegers K, Van Duijn CM. (2001). Alzheimer's disease: Genes, pathogenesis and risk prediction. Community Genet, 4, 197-203.
210. Sloley BD, Urichuk LJ, Morley P, Durkin J, Shan JJ, Pang PK, Coutts RT. (2000). Identifcation of kaempferol as a monoamine oxidase inhibitor and potential neuroprotectant in extracts of Ginkgo biloba leaves. J Pharm Pharmacol, 52, 451-459.
211. Soto C. (2001). Protein misfolding and disease; protein refolding and therapy. FEBS Lett, 498, 204-207.
212. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. (1997). Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
213. Spiteller G. (1993). Review: On the chemistry of oxidative stress. J Lipid Mediat, 7, 199-221.
214. Srinivasan M, Sudheer AR, Menon V P. (2007). Ferulic acid: Terapeutic potential through its antioxidant property. J Clin Biochem Nutr, 40, 92-100.
215. Staford GI, Pedersen PD, Jäger AK, Staden JV. (2007). Monoamine oxidase inhibition by southern African traditional medicinal plants. South Afr J Bot, 73, 384-390.
216. Stajner D, Milic N, Canadanovic-Brunet J. (1999). An investigation into the antioxidant activity of Allium nutans L. Phytother Res, 13, 333-336.
217. Stojanovic S, Sprinz H, Brede O. (2001). Efciency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys, 391, 79-89.
218. Stoll S, Scheuer K, Pohl O, Müller WE. (1996). Ginkgo biloba extract (EGb 761) independently improves changes in passive avoidance learning and brain membrane fuidity in the aging mouse. Pharmacopsychiatry, 29, 144-149.
219. Sugaya K, Uz T, Kumar V, Manev H. (2000). New anti-infammatory treatment strategy in Alzheimer's disease. Jpn J Pharmacol, 82, 85-94.
220. Sung SH, Kang SY, Lee KY, Park MJ, Kim JH, Park JH, Kim YC, Kim J, Kim YC. (2002). (+)-Alpha-viniferin, a stilbene trimer from Caragana chamlague, inhibits acetylcholinesterase. Biol Pharm Bull, 25, 125-127.
221. Tang W, Eisenbrand G. (1992). Chinese drugs of plant origin. Berlin Heidelberg: Springer-Verlag.
222. Tang XC, Han YF. (1999). Pharmacological profle of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Rev, 5, 281-300.
223. Tang XC. (1996). Huperzine A (shuangyiping): A promising drug for Alzheimer's disease. Zhongguo Yao Li Xue Bao, 17, 481-484.
224. Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, Hasegawa M. (2005). Inhibition of heparin-induced tau flament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem, 280, 7614-7623.
225. Tanner CM, Goldman SM. (1996). Epidemiology of Parkinson's disease. Neurol Clin, 14, 317-335.
226. Tanzi RE, Bertram L. (2001). New frontiers in Alzheimer's disease genetics. Neuron, 32, 181-184.
227. Terasawa K, Shimada Y, Kita T. (1997). Choto-san in the treatment of vascular dementia: A double blind, placeb-controlled study. Phytomedicine, 4, 15-22.
228. Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Wesnes KA, Scholey AB. (2005). Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol Behav, 83, 699-709.
229. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Tal LJ, Corey-Bloom J. (2000). Cholinergic dysfunction in diseases with Lewy bodies. Neurology, 54, 407-411.
230. Tohda C, Kuboyama T, Komatsu K. (2000). Dendrite extension by methanol extract of Ashwagandha (roots of Withania somnifera) in SK-N-SH cells. Neuroreport, 11, 1981-1985.
231. Topic B, Tani E, Tsiakitzis K, Kourounakis PN, Dere E, Hasenöhrl RU, Häcker R, Mattern CM, Huston JP. (2002). Enhanced maze performance and reduced oxidative stress by combined extracts of zingiber ofcinale and ginkgo biloba in the aged rat. Neurobiol Aging, 23, 135-143.
232. Tsai SH, Lin-Shiau SY, Lin JK. (1999). Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol, 126, 673-680.
233. Tuntipopipat S, Muangnoi C, Chingsuwanrote P, Parengam M, Chantravisut P, Charoenkiatkul S, Svasti S. (2011). Anti-infammatory activities of red curry paste extract on lipopolysaccharide-activated murine macrophage cell line. Nutrition, 27, 479-487.
234. Upton R. (2000). Ashwagandha root. Withania somnifera: analytical, quality control and therapeutic monograph. Santa Cruz: American Herbal Pharmacopoeia and Terapeutic Compendium, 1-25.
235. Urbain A, Marston A, Queiroz EF, Ndjoko K, Hostettmann K. (2004). Xanthones from Gentiana campestris as new acetylcholinesterase inhibitors. Planta Med, 70, 1011-1014.
236. Uto T, Qin GW, Morinaga O, Shoyama Y. (2012). 17-Hydroxy-jolkinolide B, a diterpenoid from Euphorbia fscheriana, inhibits infammatory mediators but activates heme oxygenase-1 expression in lipopolysaccharide-stimulated murine macrophages. Int Immunopharmacol, 12, 101-109.
237. Vassar R. (2004). BACE1: The β secretase enzyme in Alzheimer's disease. J Mol Neurosci, 23, 105-113.
238. Wang JY, Wen LL, Huang YN, Chen YT, Ku MC. (2006). Dual efects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated infammation. Curr Pharm Des, 12, 3521-3533.
239. Wang LM, Mineshita S. (1996). Preventive efects of unsei-in and oren-gedoku-to, Chinese traditional medicines, against rat paw oedema and abdominal constriction in mice. J Pharm Pharmacol, 48, 327-331.
240. Wang M, Kikuzaki H, Zhu N, Sang S, Nakatani N, Ho CT. (2000). Isolation and structural elucidation of two new glycosides from sage (Salvia ofcinalis L.). J Agric Food Chem, 48, 235-238.
241. Wang SW, Wang YJ, Su YJ, Zhou WW, Yang SG, Zhang R, Zhao M, Li YN, Zhang ZP, Zhan DW, Liu RT. (2012). Rutin inhibits β-amyloid aggregation and cytotoxicity, attenuates oxidative stress, and decreases the production of nitric oxide and proinfammatory cytokines. Neurotoxicology, 33, 482-490.
242. Wang YH, Du GH. (2009). Ginsenoside Rg1 inhibits beta-secretase activity in vitro and protects against Abeta-induced cytotoxicity in PC12 cells. J Asian Nat Prod Res, 11, 604-612.
243. Watson GS, Craft S. (2003). The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs, 17, 27-45.
244. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. (2001). A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 414, 212-216.
245. Welton AF, Tobias LD, Fiedler-Nagy C, Anderson W, Hope W, Meyers K, Cofey JW. (1986). Efect of favonoids on arachidonic acid metabolism. Prog Clin Biol Res, 213, 231-242.
246. Wettstein A. (2000). Cholinesterase inhibitors and Gingko extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efcacy studies of at least six months' duration. Phytomedicine, 6, 393-401.
247. Whitehouse PJ, Hedreen JC, White CL 3rd, Price DL. (1983). Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol, 13, 243-248.
248. Xue Y, Wang Y, Feng DC, Xiao BG, Xu LY. (2008). Tetrandrine suppresses lipopolysaccharide-induced microglial activation by inhibiting NF-kappaB pathway. Acta Pharmacol Sin, 29, 245-251.
249. Yamada H, Yabe T. (1997). Anti-dementia actions of Kampo (Japanese-herbal) medicines efects of kampo medicines on central nervous system. Curr top phytochem, 1, 157-168.
250. Yamaguchi Y, Higashi M, Kobayashi H. (1996). Efects of ginsenosides on impaired performance caused by scopolamine in rats. Eur J Pharmacol, 312, 149-151.
251. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, Suh HW, Kim YH, Song DK. (2001). Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol, 133, 89-96.
252. Yao Z, Drieu K, Papadopoulos V. (2001). The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived difusible neurotoxic ligands. Brain Res, 889, 181-190.
253. Yarnell E. (1998). Lemon balm. Alternat Complement Ter, 4, 417-419.
254. Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L. (2000). Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci, 173, 40-44.
255. Youdim MB, Buccafusco JJ. (2005). CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J Neural Transm, 112, 519-537.
256. Zaccai J, McCracken C, Brayne C. (2005). A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing, 34, 561-566.
257. Zarotsky V, Sramek JJ, Cutler NR. (2003). Galantamine hydrobromide: An agent for Alzheimer's disease. Am J Health Syst Pharm, 60, 446-452.
258. Zeng KW, Fu H, Liu GX, Wang XM. (2010). Icariin attenuates lipopolysaccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-kappaB and JNK/p38 MAPK pathways. Int Immunopharmacol, 10, 668-678.
259. Zga N, Papastamoulis Y, Toribio A, Richard T, Delaunay JC, Jeandet P, Renault JH, Monti JP, Mérillon JM, Wafo-Téguo P. (2009). Preparative purifcation of antiamyloidogenic stilbenoids from Vitis vinifera (Chardonnay) stems by centrifugal partition chromatography. J Chromatogr B Analyt Technol Biomed Life Sci, 877, 1000-1004.
260. Zhang HY. (2005). One-compound-multiple-targets strategy to combat Alzheimer's disease. FEBS Lett, 579, 5260-5264.
261. Zhang X, Kuang P, Wu W, Takemichi K, Kogo O, Hirobumi M, Yasaburo O. (1994a). The efect of Radix salvia miltiorrhizae composite on peroxidation of low density lipoprotein due to copper dichloride. JTCM, 14, 195-201.
262. Zhang JT, Qu ZW, Liu Y, Deng HL. (1990). Preliminary study on antiamnestic mechanism of ginsenoside Rg1 and Rb1. Chin Med J, 103, 932-938.
263. Zhao BL, Jiang W, Zhao Y, Hou JW, Xin WJ. (1996). Scavenging efects of Salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int, 38, 1171-1182.
264. Zhu Y, Bickford PC, Sanberg P, Giunta B, Tan J. (2008). Blueberry opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activation protein kinase. Rejuvenation Res, 11, 891-901.
265. Zhu Z, Li C, Wang X, Yang Z, Chen J, Hu L, Jiang H, Shen X. (2010). 2, 2', 4'-Trihydroxychalcone from Glycyrrhiza glabra as a new specifc BACE1 inhibitor efciently ameliorates memory impairment in mice. J Neurochem, 114, 374-385.
266. Zigmond JM, Burke ER. (2002). Pathophysiology of Parkinson's disease. In: Fifth Generation of Progress. Davis KL, Coyle J, Charney D, eds. Philadelphia: Lippincott, Williams and Wilkens, 1781-1794.